ABO血型不合异基因造血干细胞移植受者血型检测与血液成分输注专家共识

Expert consensus on recipient blood type test and blood component transfusion after ABO-incompatibility hematopoietic stem cell transplantation

目前ABO血型不合造血干细胞移植(HSCT)占整体HSCT的30%~50%,ABO血型不合已不是造血干细胞移植的主要障碍。输血治疗是HSCT患者移植过程的重要支持治疗,而正确的血型定型和血液成分的选择显得尤为重要。对于ABO血型不合的HSCT患者,在移植前、中、后不同时期应采用何种技术完成ABO血型检测并出具检验报告,如何选择血液成分同时兼顾输注安全与疗效,一直是困扰临床输血工作者的难点问题之一。本共识由国内输血医学和血液病学专家共同深入探讨后完成,提取7条推荐意见,旨在进一步规范、细化ABO血型不合HSCT患者血型检测和血液成分输注策略,为实现HSCT患者血型检测规范报告和血液成分精准输注、不断提高输血安全和输注疗效提供技术支撑。

At present,ABO-incompatibility hematopoietic stem cell transplantation(ABOi-HSCT)accounts for 30%~50% of the total HSCT,and is no longer a major obstacle to HSCT.Transfusion therapy is an important treatment for HSCT patients during transplantation,and correct blood typing and blood selection of blood component are particularly important.For patients with ABOi-HSCT,one of the challenging issues for laboratory technician is to complete ABO blood group testing and report before,during,and after ABOi-HSCT,as well as the selection of blood components that balance transfusion safety and efficacy.This consensus was jointly discussed by domestic experts in transfusion medicine and hematology in China,and 7 recommended opinions were extracted to further standardize the blood typing and blood component infusion strategies for ABOi-HSCT patients,provide technical support for standardized blood typing reports and accurate blood component infusion for HSCT patients,and continuously improve the safety and efficacy of blood transfusion.